Xiaoping Wang
Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (14)
Year:
2026
Previous TGIRT-seq analysis of RNAs in Inflammatory Breast Cancer (IBC) patient tumors, peripheral blood mononuclear cells (PBMCs) and plasma identified a short T-cell receptor mRNA fragment ( TRBJ1-6 ) as a potential IBC biomarker that was detected in plasma samples from IBC patients but not patients with non-inflammatory breast cancer or healthy donors. Here, we traced the origin of this TRBJ1-6 RNA fragment to IBC patient PBMCs and used a high-throughput RT-PCR/Cas12a assay with larger numbers of samples to confirm its prevalence in IBC patient PBMCs. Detection of this RNA was enhanced by T4 polynucleotide kinase treatment, indicating the presence of a 2’,3’-cyclic phosphate. Analysis of previous TGIRT-seq datasets revealed gene expression differences in IBC patient PBMCs that could contribute to TRBJ1-6 RNA prevalence in IBC patient PBMCs and plasma. Our results support the identification of the TRBJ1-6 RNA fragment as a novel, readily detectable blood-based RNA biomarker derived from IBC-patient immune cells, addressing a major unmet need for diagnosing IBC. Teaser A novel type of blood-based biomarker for diagnosis of Inflammatory Breast Cancer
Year:
2025
Somatic mutations identified by whole exome sequencing. Oncoplot representing the most common somatic mutations assessed by whole exome sequencing (WES) in tumors obtained from patients (n = 23) at the time of diagnosis. Genes with mutations occurring in five or more patients are shown.
Year:
2025
Purpose: Epidermal growth factor receptor (EGFR) pathway activation causes chemotherapy resistance, and inhibition of the EGFR pathway sensitizes triple-negative breast cancer (TNBC) cells to chemotherapy in preclinical models. Given the high prevalence of EGFR overexpression in TNBC, we conducted a single-arm phase II study of panitumumab (anti-EGFR monoclonal antibody), carboplatin, and paclitaxel as the second phase of neoadjuvant therapy (NAT) in patients with doxorubicin and cyclophosphamide (AC)–resistant TNBC (NCT02593175). Patients and Methods: Patients with early-stage, AC-resistant TNBC, defined as disease progression or ≤80% reduction in tumor volume after four cycles of AC, were eligible for this study and received panitumumab (2.5 mg/kg i.v., every week × 13), paclitaxel (80 mg/m 2 i.v. every week × 12), and carboplatin (AUC = 4 i.v., every 3 weeks × 4) as the second phase of NAT. A two-stage Gehan-type design was used to detect an improvement in the pathological complete response (pCR)/residual cancer burden class I (RCB-I) rate from 5% to 20%. Whole-exome sequencing was performed on diagnostic tumor biospecimens, where available. Results: From November 3, 2016, through August 23, 2021, 43 patients with AC-resistant TNBC were enrolled. The combined pCR/RCB-I rate was 30.2%. The most common treatment-related adverse events were neutropenia (72%) and anemia (61%), with 7 (16%), 16 (37%), and 8 (19%) patients experiencing grade 4 neutropenia, grade 3 neutropenia, and grade 3 anemia, respectively. No new safety signals were observed. Conclusions: This study met its primary endpoint (pCR/RCB-I = 30.2% vs. 5% in historical controls), suggesting that panitumumab should be evaluated as a component of NAT in patients with chemotherapy-resistant TNBC in a larger, randomized clinical trial. Significance: The epidermal growth factor receptor (EGFR) pathway has been implicated as a driver of chemotherapy resistance in triple-negative breast cancer (TNBC). Here, we evaluate the combination of panitumumab, carboplatin, and paclitaxel as the second phase of neoadjuvant therapy (NAT) in patients with AC-resistant TNBC. This study met its primary efficacy endpoint, and molecular alterations in EGFR pathway genes did not seem to influence response to the study regimen.
Year:
2025
Response to AC. Waterfall plot showing percent sonographic volumetric change to initial AC chemotherapy received prior to enrollment in study. One of the 43 patients enrolled in this study is not represented on this plot as an ultrasound was not done at the end of AC. Colors represent the total number of cycles of AC received prior to enrollment in study (red = 1; gray = 2; blue = 4). Horizontal dashed line indicates an 80% decrease in calculated tumor volume when compared with baseline measurements.
Year:
2024
Genomic alterations and pathological response to therapy. Oncoplot showing somatic mutations in the EGFR pathway assessed by WES for each patient sample obtained at the time of diagnosis ( n = 23). TMB was defined as the number of somatic mutations per megabase (Mb) of the sequenced genome.
Year:
2024
Somatic mutations identified by whole exome sequencing. Oncoplot representing the most common somatic mutations assessed by whole exome sequencing (WES) in tumors obtained from patients (n = 23) at the time of diagnosis. Genes with mutations occurring in five or more patients are shown.
Year:
2024
Survival outcomes. A, Kaplan–Meier plot of EFS for all patients. B, Kaplan–Meier plot of EFS separated by pathological response. C, Kaplan–Meier plot of MFS for all patients. D, Kaplan–Meier plot of MFS separated by pathological response. E, Kaplan–Meier plot of OS for all patients. F, Kaplan–Meier plot of OS separated by pathological response.
Year:
2024
Supplementary Figure 7. T-cell activation observed as changes in peripheral blood T-cell receptor repertoire after 2 courses of pembrolizumab maintenance therapy. The boxplot shows the interquartile range with whiskers extending up to 1.5 times the interquartile range.
Year:
2024
Supplementary Figure 7. T-cell activation observed as changes in peripheral blood T-cell receptor repertoire after 2 courses of pembrolizumab maintenance therapy. The boxplot shows the interquartile range with whiskers extending up to 1.5 times the interquartile range.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (22)
Naoto Ueno
Professor of Medicine
University of Hawai'i Cancer Center
Yu Shen
Professor
The University of Texas MD Anderson Cancer Center
Jennifer K. Litton
Professor
The University of Texas MD Anderson Cancer Center
Toshiaki Iwase
Assistant professor, Investigator-Initiated Early Phase Clinical Trial Development and Regulatory Director
University of Hawai'i Cancer Center
Anil Korkut
The University of Texas MD Anderson Cancer Center
Jeffrey Chang
The University of Texas Health Science Center at Houston
Gabriel N. Hortobagyi
The University of Texas MD Anderson Cancer Center
Jun Yao
University of Texas at Austin
James Reuben
Professor
The University of Texas MD Anderson Cancer Center
Bora Lim
Associate Professor
The University of Texas MD Anderson Cancer Center
Ryan Sun
Assistant Professor
The University of Texas MD Anderson Cancer Center
Elizabeth Mittendorf
Harvard University
Banu K. Arun
The University of Texas MD Anderson Cancer Center
Alan M. Lambowitz
University of Texas at Austin
Alexandre Reuben
Assistant Professor
The University of Texas MD Anderson Cancer Center
Alastair M Thompson
Professor of Surgery
Baylor College of Medicine
Lei Huo
The University of Texas MD Anderson Cancer Center
Evan Cohen
Assistant Professor
The University of Texas MD Anderson Cancer Center
Senthil Damodaran
The University of Texas MD Anderson Cancer Center
Wendy Woodward
Professor
The University of Texas MD Anderson Cancer Center
Ken Chen
Professor
The University of Texas MD Anderson Cancer Center
Miral M Patel
The University of Texas MD Anderson Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.